Mechanism of Action

Dial DOXILine™ for reimbursement information

The DOXIL® Difference

  • Anthracyclines, used alone or in combination with other agents, have long been an integral part of some of the most active therapies for hematologic and solid tumors1,2
  • DOXIL®—the first and only pegylated liposomal drug approved by the US Food and Drug Administration3
  • The pegylated liposomal formulation of DOXIL® has different pharmacokinetics than conventional doxorubicin HCi4

The DOXIL® Difference

Defining DOXIL® Innovation

  • The pegylated liposomal coating allows DOXIL® to evade detection and destruction by the immune system and, as a result, increase the blood circulation time*
    • Half-life of approximately 55 hours
    • Remains stable in blood
    • ≥90% of the drug stays encapsulated within the liposome during circulation
  • Unlike doxorubicin, which displays a large volume of distribution, DOXIL® has a small steady state and, therefore, is confined mostly to the vascular fluid
  • The clinical significance of the clinical pharmacology data has not been determined.

Defining DOXIL® Innovation

*The exact mechanism for the release of the encapsulated doxorubicin HCl is not well understood.

†A pharmacokinetic study analyzed DOXIL® vs free doxorubicin at 2 doses in cancer patients
(N=16). Group 1 (n=7) received free doxorubicin followed by DOXIL® at the same dose (25 mg/m2
[n=3] or 50 mg/m2 [n=4]). Group 2 (n=9) received only DOXIL® in both treatments. Patients were
given either 25 mg/m2 or 50 mg/m2 up front, followed by a second course of 50 mg/m2. At
baseline, patients (male/female, 6/10) had a median performance status of 2 (range, 1-3) and a
median age of 59.5 years (range, 38-73). The study included patients with different tumor types,
including patients with ovarian cancer and patients with breast cancer. There were no patients with
multiple myeloma in this study population.